Breaking News Instant updates and real-time market news.

ZGNX

Zogenix

$13.30

0.45 (3.50%)

16:17
11/22/16
11/22
16:17
11/22/16
16:17

Zogenix: New data on Zogenix's ZX008 to be presented at AES meeting

Zogenix announced the presentation of four clinical and scientific posters, and the hosting of a scientific exhibit room at the 70th Annual American Epilepsy Society meeting, which will take place at the George R. Brown Convention Center in Houston, Texas, from December 2 - 6, 2016. Four posters highlighting the results of investigator initiated studies will be available in the main exhibitor hall of the congress. One poster will highlight the interim results for patients who have completed at least 8 weeks of treatment in a Phase 2 study of ZX008 in Lennox Gastaut syndrome. The second poster will provide an update from the ongoing open-label prospective study of ZX008 in Dravet syndrome. A third poster will be the first to evaluate the potential protective effect of fenfluramine in an accepted pre-clinical model of Sudden Unexpected Death in Epilepsy. The fourth poster will discuss findings from roundtable discussions with parents and caregivers of children with Dravet syndrome that sought to identify those aspects of caregivers' lives that are most impacted by caring for a child with Dravet syndrome.

  • 29

    Nov

ZGNX Zogenix
$13.30

0.45 (3.50%)

11/25/15
LEER
11/25/15
NO CHANGE
LEER
Outperform
Zogenix epilepsy meeting abstracts encouraging, says Leerink
Leerink analyst Paul Matteis noted that three abstracts to be presented by Zogenix at the American Epilepsy Society were made available this morning, stating that new data on seven additional patients treated with fenfluramine add support to the clinical potential of the drug as a Dravet Syndrome treatment. Matteis reiterates an Outperform rating on Zogenix.
05/05/16
LEER
05/05/16
NO CHANGE
LEER
Outperform
Zogenix drug showing 'encouraging efficacy' across seizure types, says Leerink
Leerink analyst Paul Matteis believes that the median seizure reduction demonstrated by Zogenix's (ZGNX) ZX008 compares favorably to the reduction in convulsive seizures seen in the placebo arm of the recent GW Pharmaceuticals (GWPH) Epidiolex phase 3 Dravet study, though he noted that Zogenix data represents a small sample and was generated at a single clinical site. Still, the new data continues to reflect ZX008's "encouraging efficacy across various types of motor seizures" and the drug's safety data also look favorable, Matteis tells investors. The firm keeps an Outperform rating on Zogenix shares.
10/04/16
LEER
10/04/16
INITIATION
Target $17
LEER
Outperform
Zogenix reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Zogenix with an Outperform rating and $17 price target.
11/11/16
AGIS
11/11/16
INITIATION
Target $28
AGIS
Buy
Zogenix initiated with a Buy at Aegis
Target $28.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.